All Peptides
Every compound in the REGEN library, listed alphabetically with its evidence grade, category, and standard dose.
| Compound | Category | Grade | Standard dose | Half-life | Status |
|---|---|---|---|---|---|
| 5-Amino-1MQ | Weight Loss | C-grade | 50–150 mg · 1x daily | Not reported | Research |
| Adamax | Longevity | F-grade | 300–600 mcg · 1-2x daily | ~2–4 hours | Research |
| AHK-Cu (Copper Tripeptide-3) | Aesthetics | D-grade | Topical: per-serum concentration · Injectable: no standardized dose · varies by form | Not reported | Research |
| BPC-157 | Recovery | C-grade | 250–500 mcg · 1-2x daily | ~Under 30 minutes in animal PK | Research |
| BPC-157 + TB-500 Blend | Recovery | B-grade | BPC 250–500 mcg · TB 2–5 mg · BPC daily · TB 1-2x weekly | Not reported | Research |
| CJC-1295 (DAC) | Performance | D-grade | 1–2 mg · 1-2x weekly | ~6-8 days | Research |
| CJC-1295 (no-DAC) | Performance | C-grade | 100–300 mcg · 1-2x daily | ~6-8 days | Research |
| CJC-1295 (no-DAC) + Ipamorelin Blend | Performance | C-grade | CJC 100–300 mcg · Ipa 200–300 mcg · 1-2x daily, pre-bed | Not reported | Research |
| Dihexa | Cognitive | F-grade | 5–20 mg · 1x daily | Not reported | Research |
| DSIP (Delta Sleep-Inducing Peptide) | Recovery | D-grade | 100–300 mcg · before bed | ~7-8 minutes | Research |
| Epithalon | Longevity | D-grade | 5–10 mg · daily, 10–20 day cycles | Not reported | Research |
| Exenatide | Weight Loss | S-grade | 5–10 mcg BID · 2mg weekly (XR) · see formulation | ~2.4 hours | FDA-approved |
| Follistatin-344 | Performance | F-grade | 100–300 mcg · 1x daily | Not reported | Research |
| GHK-Cu | Aesthetics | C-grade | 1–2 mg · 1x daily (injectable) | Not reported | Research |
| GHRP-2 | Performance | C-grade | 100–300 mcg · 1-3x daily | ~15-60 minutes | Research |
| GHRP-6 | Performance | D-grade | 100–300 mcg · 1-3x daily | ~15-60 minutes | Research |
| GLOW Blend | Aesthetics | B-grade | ~2.33 mg total blend · daily | Not reported | Research |
| Glutathione | Recovery | D-grade | 200–1000 mg · route-dependent | Not reported | Research |
| Gonadorelin | Performance | C-grade | 100 mcg · 2–3x weekly | ~10-40 minutes | FDA-approved |
| hCG (Human Chorionic Gonadotropin) | Performance | S-grade | 250–500 IU · 2–3x weekly | ~24-36 hours | FDA-approved |
| Humanin | Longevity | C-grade | 1–2 mg · 1x daily | Not reported | Research |
| IGF-1 LR3 | Performance | F-grade | 20–50 mcg · 1x daily | ~20-30 hours | Research |
| Ipamorelin | Performance | C-grade | 200–300 mcg · 1-3x daily | ~ 2 hours | Research |
| Kisspeptin-10 | Performance | B-grade | ~100 mcg · research protocol-dependent | Not reported | Research |
| KLOW Blend | Recovery | C-grade | 250–750 mcg total blend · daily | Not reported | Research |
| KPV | Recovery | D-grade | 200–500 mcg · 1x daily | Not reported | Research |
| Larazotide | Recovery | D-grade | 0.5 mg · 3x daily | Not reported | Research |
| Liraglutide | Weight Loss | S-grade | 0.6–3.0 mg · 1x daily (titrated) | ~13 hours | FDA-approved |
| LL-37 | Recovery | D-grade | No standardized dose · no established human protocol | Not reported | Research |
| Melanotan I (Afamelanotide) | Aesthetics | B-grade | 16 mg implant · 1x monthly | ~30-50 minutes | Research |
| Melanotan II | Aesthetics | B-grade | 250–500 mcg · as needed (loading then maintenance) | ~ 1 hour | Research |
| MK-677 | Performance | A-grade | 10–25 mg · once daily | ~ 24 hours | Research |
| MOTS-c | Longevity | C-grade | 5–10 mg · 2-3x weekly | Not reported | Research |
| NAD+ | Recovery | C-grade | 50–750 mg · route-dependent | Not reported | Research |
| Orforglipron | Weight Loss | S-grade | 0.8–17.2 mg · 1x daily (titrated) | ~29–49 hours | FDA-approved |
| Oxytocin | Longevity | B-grade | 20–40 IU · intranasal, pre-activity | ~3-5 minutes | Research |
| Pinealon | Longevity | F-grade | 5–10 mg · daily, 10–20 day cycles | Not reported | Research |
| PT-141 | Performance | S-grade | 0.5–2 mg · as needed, before activity | ~2.7 hours | FDA-approved |
| Retatrutide | Weight Loss | A-grade | 1–12 mg · 1x weekly (titrated) | ~ 6 days | Research |
| Selank | Cognitive | C-grade | 250–300 mcg · 1-3x daily (intranasal) | Not reported | Research |
| Semaglutide | Weight Loss | S-grade | 0.25–2.4 mg · 1x weekly (titrated) | ~ 7 days | FDA-approved |
| Semax | Cognitive | B-grade | 300–600 mcg · 1-2x daily (intranasal) | Not reported | Research |
| Sermorelin | Performance | C-grade | 200–300 mcg · pre-bed | ~10-20 minutes | Research |
| SLU-PP-332 | Longevity | D-grade | 25–50 mg · 1x daily | Not reported | Research |
| SLU-PP-915 | Longevity | D-grade | 10–25 mg · 1x daily | Not reported | Research |
| SNAP-8 | Aesthetics | D-grade | Per product concentration · topical, 1-2x daily | Not reported | Research |
| Somatropin (HGH) | Performance | S-grade | Individualized by indication · daily, physician-titrated | ~20–30 minutes | Research |
| SS-31 (Elamipretide) | Longevity | B-grade | 40 mg · 1x daily | ~7-10 hours | Research |
| TB-500 | Recovery | D-grade | 2–5 mg · 2x weekly (loading), then 1x weekly | ~30–60 min | Research |
| Tesamorelin | Weight Loss | S-grade | 1–2 mg · 1x daily | ~26-38 minutes | FDA-approved |
| Tesamorelin + Ipamorelin Blend | Performance | B-grade | Tesa 1–2 mg · Ipa 200–300 mcg · Tesa 1x daily · Ipa 1-3x daily | Not reported | Research |
| Thymosin Alpha-1 | Longevity | A-grade | 1.6 mg · 2x weekly | ~2 hours | Research |
| Tirzepatide | Weight Loss | S-grade | 2.5–15 mg · 1x weekly (titrated) | ~ 5 days | FDA-approved |
| VIP (Vasoactive Intestinal Peptide) | Longevity | C-grade | 50–300 mcg · 1–2x daily | ~1 minute | Research |